**University of the Philippines Manila**
*The Health Sciences Center*
**BIDS & AWARDS COMMITTEE IV (BAC IV)**

**Proj. Ref. No.** **BAC4-21- 028**
**End-User** **Property and Supply Division** **Opening of Bids:** **19 November 2021**
**Project** **SUPPLY & DELIVERY OF VARIOUS DRUGS AND MEDICINES FOR COVID-19 TREATMENT FOR CY 2022 (FRAMEWORK AGREEMENT)**

| ITEM NO. | QTY | UNIT | ITEM DESCRIPTION | ABC PER UNIT (PHP) | QUOTATIONS (all taxes included) | |
|---|---|---|---|---|---|---|
| | | | | | in figures | in words |
| 1 | 5,400 | Pc. | Tocilizumab 400mg/ 20ml vial concentrate solution for IV Infusion | 20,581.45 | | |
| 2 | 13,200 | Pc. | Remdesivir 100mg vial lyophilized powder for injection for IV Infusion or 100mg/20ml solution for IV infusion (With Compassionate Special Permit) | 2,589.29 | | |
| 3 | 48,000 | Pc. | Enoxaparin sodium 100mg/mL, 0.4mL pre-filled syringe (SC) | 699.99 | | |
| 4 | 16,800 | Pc. | Enoxaparin sodium 100mg/mL, 0.6mL pre-filled syringe (SC) | 917.00 | | |
| 5 | 60,000 | Pc. | Dexamethasone sodium phoshate 4 mg/mL, 2 mL ampul/vial (IM, IV) | 17.88 | | |
| 6 | 38,400 | Pc. | Diphenhydramine Hydrochloride 50 mg/mL, 1 mL ampul (IM, IV) | 11.22 | | |
| 7 | 11,040 | Pc. | Heparin sodium unfractionated 1,000 iu/mL, 5mL vial (IV infusion, SC) (bovine origin) | 78.34 | | |
| 8 | 7,440 | Pc. | Heparin sodium unfractionated 5000 IU/mL, 5 mL vial (IV infusion, SC) (bovine origin) | 220.80 | | |
| 9 | 348,000 | Pc. | Paracetamol 150mg/mL, 2mL ampule solution for injection (IM, IV) | 25.00 | | |
| 10 | 78,000 | Pc. | Omeprazole powder, 40 mg vial + 10 mL solvent ampul/vial (IV) | 25.87 | | |
| 11 | 108,000 | Pc. | Epinephrine Hydrochloride 1mg/mL, 1mL ampule (IV, IM, SC) | 45.00 | | |
| 12 | 66,000 | Pc. | Norepinephrine bitartrate 1mg/mL, 4mL ampule (IV infusion) | 82.33 | | |
| 13 | 33,600 | Pc. | Nicardipine Hydrochloride 1mg/mL, 10mL ampule (IV) | 105.00 | | |
| 14 | 600 | Pc. | Vasopressin 20iu/mL solution for injection, 1mL ampule (With Compassionate Special Permit) | 1,490.00 | | |
| 15 | 2,400 | Pc. | Ceftazidime penhydrate + Avibactam sodium 2g/0.5g powder concentrate for infusion vial | 6,720.00 | | |
| 16 | 36,000 | Pc. | Dexmedetomidine 200mcg/2mL (100mcg/mL) single-dose glass vial | 2,219.38 | | |
| 17 | 7,200 | Pc. | Rocuronium bromide 10 mg/mL, 5 mL ampul/vial (IV) | 151.89 | | |
| 18 | 18,000 | Pc. | Propofol 10mg/mL, 20mL ampule/vial (IV) | 47.29 | | |

**University of the Philippines Manila**
*The Health Sciences Center*
**BIDS & AWARDS COMMITTEE IV (BAC IV)**

**Proj. Ref. No.** **BAC4-21- 028**
**End-User** **Property and Supply Division** **Opening of Bids:** **19 November 2021**
**Project** **SUPPLY & DELIVERY OF VARIOUS DRUGS AND MEDICINES FOR COVID-19 TREATMENT FOR CY 2022 (FRAMEWORK AGREEMENT)**

| | | | | | | |
|---|---|---|---|---|---|---|
| 19 | 90,000 | Pc. | Midazolam 1mg/mL, 5mL ampule or 5mg/mL, 1mL ampule (IM, IV) (With PDEA Permit) | 56.23 | | |
| 20 | 84,000 | Pc. | Midazolam 5mg/mL, 3mL ampule (IM, IV) (With PDEA Permit) | 198.79 | | |
| 21 | 108,000 | Pc. | Fentanyl citrate 50mcg/mL, 2mL amp (IV) (With PDEA Permit) | 188.33 | | |
| 22 | 132,000 | Pc. | Acetylcysteine 600mg effervescent tablet | 16.00 | | |
| 23 | 72,000 | Pc. | Ascorbic Acid (vitamin C) 500mg tablet | 4.00 | | |
| 24 | 33,600 | Pc. | Butamirate citrate 50mg MR tablet | 12.80 | | |
| 25 | 30,000 | Pc. | Azithromycin 500 mg tablet (as base*/as dihydrate/as monohydrate) | 79.77 | | |
| 26 | 30,000 | Pc. | Co-amoxiclav (amoxicillin + potassium clavulanate) 500 mg amoxicillin (as trihydrate) + 125mg potassium clavulanate per tablet | 26.00 | | |
| 27 | 84,000 | Pc. | Omeprazole 40mg capsule | 3.07 | | |
| 28 | 3,600 | Pc. | Oral Rehydration Salts (ORS 75-replacement)<br>Composition of reduced osmolarity ORS per liter of water (WHO recommended)<br>Sodium chloride - 2.6 g<br>Trisodium citrate dihydrate - 2.9 g | 5.88 | | |
| 29 | 84,000 | Pc. | Paracetamol 500mg tablet | 2.65 | | |
| 30 | 6,000 | Pc. | Salbutamol sulfate 100 micrograms/dose x 200 actuations Metered Dose Inhaler (MDI) | 118.54 | | |
| 31 | 43,200 | Pc. | Salbutamol sulfate Resp. Soln.: (for nebulization) 1 mg/mL, 2.5 mL (unit dose) | 6.00 | | |
| 32 | 8,400 | Pc. | Ipratropium + Salbutamol MDI: 20 micrograms ipratropium (as bromide) + 100 micrograms salbutamol x 200 doses x 10 mL | 924.00 | | |
| 33 | 45,600 | Pc. | Ipratropium + Salbutamol Resp. Soln.: (for nebulization) 500 micrograms ipratropium (as bromide anhydrous) + 2.5 mg salbutamol (as base) x 2.5 mL (unit dose) | 14.29 | | |
| 34 | 840 | Pc. | Budesonide 160 micrograms + Formoterol (as fumarate dihydrate) 4.5 micrograms x 120 doses with appropriate accompanying dispenser MDI | 651.14 | | |
| 35 | 360 | Pc. | Budesonide 160 micrograms + Formoterol (as fumarate dihydrate) 4.5 micrograms x 60 doses with appropriate accompanying dispenser DPI | 835.47 | | |

**University of the Philippines Manila**
*The Health Sciences Center*
**BIDS & AWARDS COMMITTEE IV (BAC IV)**

**Proj. Ref. No.** **BAC4-21- 028**
**End-User** **Property and Supply Division** **Opening of Bids:** **19 November 2021**
**Project** **SUPPLY & DELIVERY OF VARIOUS DRUGS AND MEDICINES FOR COVID-19 TREATMENT FOR CY 2022 (FRAMEWORK AGREEMENT)**

| | | | | | | |
|---|---|---|---|---|---|---|
| 36 | 240 | Pc. | Glycopyrronium (as bromide) + Indacaterol (as maleate) Inhalation: 50mcg/110mcg inhalation powder in hard capsules | 69.42 | | |
| 37 | 60 | Pc. | Fluticasone propionate+salmeterol xinafoate MDI 250mcg/25mcg x 120 actuations with dose counter | 220.44 | | |
| 38 | 4,800 | Pc. | Zinc solution (equiv. to 20 mg elemental zinc/5mL), Syrup 60 mL (As Sulfate Monohydrate) | 92.00 | | |
| 39 | 6,000 | Pc. | Chlorhexidine solution 0.12%, 120mL (as gluconate) bottle | 120.26 | | |
| **TOTAL APPROVED BUDGET FOR THE CONTRACT: PhP381,766,965.60** | | | | | | |

Approved by:

**Dean VICENTE Y. BELIZARIO, JR., M.D.**
*Chairperson*

_____
*(Signature over Printed Name of President/Gen. Manager)*

_____
*(Name & Address of Company)*

**TERMS & CONDITIONS:**

1 Indicate the **brand and packing of the item/s** offered.

2 The brand offered must be **at least five (5) years commercially available in the market from date of opening of bids.** Proof of this shall be the initial Certificate of Product Registration (CPR) issued by the Food and Drug Administration (FDA).

3 **Submit the following documents, submission should be per product, with tab and per item number. Two (2) copies for the Valid Certificate of Product Registration and Certificate of Analysis (COA).**

a. **Memorandum of Agreement (MOA) and Certificate of exclusive/ authorized distributorship between the manufacturer and distributor.** Distributors/suppliers must have certification from their principals that they are the exclusive distributor of the drug products authorized to submit tender for the product on behalf of the principal and that all commitments made by them shall be honored by the principal in case of termination of distributorship agreement.

b. **Valid Certificate of Product Registration (CPR)** issued by the Food and Drug Administration (FDA).

**- The name of the respective distributor should appear in the submitted CPR of the drug.**

*Note: CPRs that will expire within three (3) months from the date of*

*opening of bids should present the Official Receipt of renewal of application with the Document Tracking log for the CPR from the FDA.*

c. **Certificate of Analysis (COA)** for the products offered (batch to be delivered if awarded) duly issued by an FDA accredited laboratory (local) and should contain information indicated in monograph of the drug. Sample analyzed must not be expired during the time of bidding. The result of assay submitted must be in the specific brand and should be in the exact dosage formulation of the drug being bidded. In cases where local laboratories are unavailable to perform drug assays, assays done abroad is accepted. The local COA is preferred and given more weight in the evaluation and awarding process.

d. **A notarized certificate** that it is the innovator drug (if applicable).

e. **Certificate of Good Manufacturing Process (CGMP).**

f. **Valid License to Operate (LTO).**

g. **A notarized certificate that the offered brand has not been subject to product complaint/product recall** for the past three (3) years.

h. **Certificate of Acceptance** from at least three (3) major hospitals issued within the year and should be supported with Sales Invoice (*for new item/brand offered only).*

i. **A notarized certificate** that there are sufficient stocks for the offered item/s for one (1) year.

4 The offered drug must conform to the latest Philippine Food and Drug Administration (FDA) Administrative Order **governing the generic labeling and packaging requirements.**

**4.1 For all tablets and capsules**

4.1.1 **All tablets/capsules should be in foil or blister pack. A picture of the blister pack (front and back) should be submitted.**

4.1.2 Each individual flap in the tablet or capsule blister pack should be labeled with the generic name and brand.

4.1.3 Dosage form and strength of the Active Pharmaceutical Ingredients (API) should appear on each unit or every 2 units for products with multiple APIs.

4.1.4 Name of drug, lot or batch number and expiry date must appear on every standard blister pack/foil strip and on the container or inner packing. However, if the product is not restricted for dispensing in quantities less than the standard blister pack or foil strip, the batch or lot number and expiry date should appear on each unit.

4.1.5 Inner label must be the same as the outer label.

4.1.6 A complete drug literature/product insert must accompany the product.

5 The following must be complied with specific for **inhalation anethetics and cytotoxic injectable drugs.**

**Proj. Ref. No.** **BAC4-21- 028**
**End-User** **Property and Supply Division** **Opening of Bids:** **19 November 2021**
**Project** **SUPPLY & DELIVERY OF VARIOUS DRUGS AND MEDICINES FOR COVID-19 TREATMENT FOR CY 2022 (FRAMEWORK AGREEMENT)**

**5.1 For inhalation aneshetics**

5.1.1 Submit **certification from the bidder that inhalation bottle must be with safety sealed cap,** airtight and capable to dispense directly from bottle the possibility of ambient air coming into contact with agent to prevent contamination and spillage.

5.1.2 Submit **certification from the bidder that product container or anesthetic agent is shatterproof and transparent for visual check of content.** Container material must ensure stability of the agent to prevent degradation, must not be easy to break.

5.1.3 Winning bidder for Sevoflurane shall *provide at least thirty-five (35) vaporizers* on loan and in good working conditions until the validity of the contract.

**5.2 For Cytotoxic Injectable Drugs**

5.2.1 For cytotoxic injectable drugs, winning bidders are required to *provide Material Safety Data Sheet (MSDS) and to submit Drug Profile* to the Pharmacy Department per company under the first Purchase Order.

5.2.2 Winning bidders for cytotoxic injectable drugs are required to **provide at least three (3) spill kits** per company under the first Purchase Order.

5.2.3 For Paclitaxel, a special IV set must be provided per unit of the drug.

6 **New brands offered** shall be subject to further evaluation and shall require the following:

a. Validation of the submitted Certificate of Acceptance from at least three (3) major hospitals;
b. Justification from end-user/s to validate the acceptance of the good/s offered (to be facilitated by PGH-PSD).

7 **For the supply and delivery of awarded drugs and medicines.**

7.1 Delivery of the goods is required as stated in the request of the end-user, commencing on the 3rd working day of notification through confirmed fax/email that the approved Call-off/ Notice to Supplier (NTS) is already available for pick up.

7.2 Delivery schedule (whichever is applicable):

a) within seven (7) calendar days
b) as may be called for;
c) staggered delivery within three (3) months
* 50% of the total quantity within seven (7) calendar days and 25% each for the succeeding months

*Note: The end-user has the right to adjust the quantity to be delivered depending on the actual need of the hospital*

7.3 Deliveries shall have **at least two (2) years expiration date.**

7.4 Delivery of goods **with product complaint shall be put on hold** until

**Proj. Ref. No.** **BAC4-21- 028**
**End-User** **Property and Supply Division** **Opening of Bids:** **19 November 2021**
**Project** **SUPPLY & DELIVERY OF VARIOUS DRUGS AND MEDICINES FOR COVID-19 TREATMENT FOR CY 2022 (FRAMEWORK AGREEMENT)**

receipt of the final decision of the PGH management whether to proceed with the acceptance or to cancel/return the items.

7.5 Delivered **items found to be non-formulary at any given time shall be returned** to the company and a credit memo shall be issued.

7.6 Stocks delivered **are subject to random sampling for testing** as to quality and conformity to label. Testing fee at supplier's expense.

7.7 Stocks with lot #/batch different from the submitted Certificate of Analysis (COA) will be subjected to testing as to quality and conformity to label. Testing fee at supplier's expense.

7.8 All items that had been pulled out for various reasons, a credit memo shall be issued by the Contractor within one (1) month, otherwise, a debit memo shall be processed by UP Manila - PGH and the amount will be deducted from any amount due to Supplier.

7.9 It is understood that the Supplier is legally responsible to deliver all issued **CALL-OFF/s** (Purchase Order) and **failure to deliver the first Call-Off as scheduled shall mean automatic cancellation of the Call-Off and Notice to Execute Framework Agreement (NEFA).** Purchase from other source for whatever means shall be effected immediately to provide the requirements of the hospital. Penalty to the defaulting contractor shall be charged accordingly.

8 **Failure to comply with the submission of the required documents shall be ground for post-disqualification in accordance with RA 9184.**

9 Compliance with RA 9184 and other applicable laws.

Approved by:

**Dean VICENTE Y. BELIZARIO, JR., M.D.**
*Chairperson*

_____
*(Signature over Printed Name of President/Gen. Manager)*

_____
*(Name & Address of Company)*